(PHG) Koninklijke Philips - Overview
Stock: Imaging Systems, Patient Monitoring, Respiratory Care, Oral Care, Baby Care
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.99% |
| Yield on Cost 5y | 1.96% |
| Yield CAGR 5y | -1.64% |
| Payout Consistency | 76.3% |
| Payout Ratio | 104.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 31.9% |
| Relative Tail Risk | -15.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.38 |
| Alpha | -2.93 |
| Character TTM | |
|---|---|
| Beta | 0.914 |
| Beta Downside | 0.948 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.81% |
| CAGR/Max DD | 0.71 |
Description: PHG Koninklijke Philips December 17, 2025
Koninklijke Philips N.V. (NYSE: PHG) is a Dutch-based health-technology firm that serves North America, Greater China, and other international markets through three operating segments: Diagnosis & Treatment, Connected Care, and Personal Health.
In Diagnosis & Treatment, Philips supplies a full suite of imaging equipment-including MRI, X-ray, CT (with detector-based spectral CT), and ultrasound systems-as well as interventional X-ray platforms and software that support minimally invasive cardiac, vascular, and electrophysiology procedures.
The Connected Care segment focuses on acute patient-management tools, emergency-care solutions, home-care platforms, and vendor-agnostic software that enable remote monitoring and workflow integration across hospitals and ambulatory settings.
Personal Health delivers consumer-oriented products such as power toothbrushes, infant-feeding devices, digital parental and women’s health solutions, and grooming/beauty items, leveraging Philips’ brand equity in the household market.
Key recent metrics (FY 2023): revenue of $21.2 billion, up ~6 % YoY; operating margin of ~10 %; and R&D spending of roughly 5 % of sales, reflecting continued investment in AI-driven imaging and digital health platforms. The global medical imaging market is projected to grow at a 5 % CAGR through 2029, driven by an aging population and rising demand for early disease detection.
Assumption: the FY 2023 figures are based on Philips’ published annual report; any forward-looking statements about market growth rely on consensus estimates from industry research firms (e.g., Grand View Research). If actual R&D intensity or margin trends diverge, the growth outlook could shift materially.
For a deeper, data-rich assessment of Philips’ valuation dynamics, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 165.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -7.37 > 1.0 |
| NWC/Revenue: 12.64% < 20% (prev -35.92%; Δ 48.56% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.11b > Net Income 165.0m |
| Net Debt (6.47b) to EBITDA (2.33b): 2.78 < 3 |
| Current Ratio: 1.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (963.8m) vs 12m ago 5.56% < -2% |
| Gross Margin: 43.49% > 18% (prev 0.42%; Δ 4307 % > 0.5%) |
| Asset Turnover: 92.95% > 50% (prev 151.3%; Δ -58.39% > 0%) |
| Interest Coverage Ratio: 4.11 > 6 (EBITDA TTM 2.33b / Interest Expense TTM 276.0m) |
Altman Z'' 2.27
| A: 0.09 (Total Current Assets 9.28b - Total Current Liabilities 7.03b) / Total Assets 26.34b |
| B: 0.12 (Retained Earnings 3.21b / Total Assets 26.34b) |
| C: 0.06 (EBIT TTM 1.13b / Avg Total Assets 19.13b) |
| D: 0.87 (Book Value of Equity 13.76b / Total Liabilities 15.76b) |
| Altman-Z'' Score: 2.27 = BBB |
Beneish M -3.35
| DSRI: 0.78 (Receivables 3.27b/4.25b, Revenue 17.78b/18.04b) |
| GMI: 0.97 (GM 43.49% / 42.18%) |
| AQI: 0.88 (AQ_t 0.56 / AQ_t-1 0.64) |
| SGI: 0.99 (Revenue 17.78b / 18.04b) |
| TATA: -0.04 (NI 165.0m - CFO 1.11b) / TA 26.34b) |
| Beneish M-Score: -3.35 (Cap -4..+1) = AA |
What is the price of PHG shares?
Over the past week, the price has changed by +2.65%, over one month by +2.65%, over three months by +4.32% and over the past year by +11.63%.
Is PHG a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PHG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.5 | 10.4% |
| Analysts Target Price | 32.5 | 10.4% |
| ValueRay Target Price | 29.8 | 1.3% |
PHG Fundamental Data Overview February 05, 2026
P/E Trailing = 152.7369
P/E Forward = 16.0256
P/S = 1.5522
P/B = 2.2168
P/EG = 0.3632
Revenue TTM = 17.78b EUR
EBIT TTM = 1.13b EUR
EBITDA TTM = 2.33b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.38b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.47b EUR (from netDebt column, last quarter)
Enterprise Value = 29.85b EUR (23.38b + Debt 8.38b - CCE 1.91b)
Interest Coverage Ratio = 4.11 (Ebit TTM 1.13b / Interest Expense TTM 276.0m)
EV/FCF = 93.81x (Enterprise Value 29.85b / FCF TTM 318.2m)
FCF Yield = 1.07% (FCF TTM 318.2m / Enterprise Value 29.85b)
FCF Margin = 1.79% (FCF TTM 318.2m / Revenue TTM 17.78b)
Net Margin = 0.93% (Net Income TTM 165.0m / Revenue TTM 17.78b)
Gross Margin = 43.49% ((Revenue TTM 17.78b - Cost of Revenue TTM 10.05b) / Revenue TTM)
Gross Margin QoQ = 44.40% (prev 46.36%)
Tobins Q-Ratio = 1.13 (Enterprise Value 29.85b / Total Assets 26.34b)
Interest Expense / Debt = 0.68% (Interest Expense 57.0m / Debt 8.38b)
Taxrate = 31.64% (87.0m / 275.0m)
NOPAT = 774.6m (EBIT 1.13b * (1 - 31.64%))
Current Ratio = 1.32 (Total Current Assets 9.28b / Total Current Liabilities 7.03b)
Debt / Equity = 0.79 (Debt 8.38b / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = 2.78 (Net Debt 6.47b / EBITDA 2.33b)
Debt / FCF = 20.34 (Net Debt 6.47b / FCF TTM 318.2m)
Total Stockholder Equity = 11.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.86% (Net Income 165.0m / Total Assets 26.34b)
RoE = 1.48% (Net Income TTM 165.0m / Total Stockholder Equity 11.16b)
RoCE = 6.16% (EBIT 1.13b / Capital Employed (Equity 11.16b + L.T.Debt 7.24b))
RoIC = 4.11% (NOPAT 774.6m / Invested Capital 18.86b)
WACC = 6.95% (E(23.38b)/V(31.76b) * Re(9.28%) + D(8.38b)/V(31.76b) * Rd(0.68%) * (1-Tc(0.32)))
Discount Rate = 9.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.52%
[DCF Debug] Terminal Value 75.26% ; FCFF base≈599.7m ; Y1≈393.7m ; Y5≈179.6m
Fair Price DCF = N/A (negative equity: EV 4.33b - Net Debt 6.47b = -2.14b; debt exceeds intrinsic value)
EPS Correlation: 10.47 | EPS CAGR: -38.38% | SUE: -4.0 | # QB: 0
Revenue Correlation: -6.22 | Revenue CAGR: -3.64% | SUE: -0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=1.75 | Chg30d=-0.069 | Revisions Net=-2 | Growth EPS=+9.1% | Growth Revenue=+1.1%